- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, January 5, 2018
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
A study published in The American Journal of Managed Care® (AJMC®) was highlighted in Becker’s Hospital Review and RevCycle Intelligence articles discussing how care coordination reduces emergency department (ED) costs. The study, “ED-Based Care Coordination Reduces Costs for Frequent ED Users,” found that patients enrolled in the program had 35% fewer ED visits and 31% fewer ED admissions, which led to a 15% reduction in ED costs. The authors concluded that future efforts to promote population health and control costs may benefit from incorporating similar programs into acute care delivery systems.
The National Pharmaceutical Council’s CER Daily Newsfeed on Thursday included 2 articles from the AJMC® newsroom. The first article, “How Value Frameworks Define Durable Survival of New Immuno-Oncology Agents,” covered a study that found new immuno-oncology agents are providing durable survival for some patients, but the cost of these treatments is very high, which is a cause for concern. The second article, “The Impact High OOP Costs Have on Patients Filling Prescriptions for Oral Cancer Drugs,” reported on study findings that concluded that while patients with cancer may have more options for oral cancer medications, high out-of-pocket costs still prevent a barrier to access.
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
